

SafeBoosC-III newsletter March 2022

Dear investigators

Welcome to the March 2022 issue of the SafeBoosC-III newsletter.

Extension of deadline for registration to SafeBoosC investigator meeting

The deadline for registration to the investigator meeting was initially 1st of April 2022. As some of you have still not responded, we have decided to extend the deadline for registration until 3rd of April 2022. Later than this, registration will not be possible.

Please send an e-mail to mathias.luehr.hansen@regionh.dk if you intend to participate, including whether you will attend physically or virtually. If you cannot participate, please let us know as well.

Please recall that during the evening session on 19th of May, the SafeBoosC-III abstract will be presented and unblinded. Therefore, only investigators who co-author the publication of the primary results may attend, as these are confidential - this is relevant for those who intend to send a delegate to the meeting.

Secondary and ancillary studies in SafeBoosC-III

On 24th of March, the online meeting on proposals for secondary studies was held. Four proposals were presented and discussed. The minutes from the meeting, including a summary of the study proposals and discussion, can be found here:

<https://www.rigshospitalet.dk/english/departments/juliane-marie-centre/departments-of-neonatology/research/SafeboosC-III/Documents/secondary-and-ancillary-studies-meeting-minutes.pdf>

Only one of three proposals could be defined as a secondary study. The definition of a secondary study, is a study that solely relies on data from the SafeBoosC-III database, while the definition of an ancillary study, is a study that includes additional data which is not a part of the SafeBoosC-III database. As three of the four studies included additional data, these are defined as ancillary studies.

The four studies were as follows.

Secondary study:

- Mechanical ventilation and late brain injury in the SafeBoosC-III trial. Gorm Greisen, Copenhagen, Denmark

Ancillary studies:

- SafeBoosC-III MRI at term age. Miguel Alsina, Barcelona, Spain

- Qualification of flow-pressure cerebral autoregulation during transition in extremely preterm infants. Liesbeth Thewissen, Leuven, Belgium
- Early cerebral desaturation events and intraventricular haemorrhage in extremely preterm infants. Gene Dempsey, Cork, Ireland

At the steering committee meeting on 28th of March, the four studies were discussed, and the secondary study were formally approved.

As for the three proposed ancillary study, the responsible investigators are in the process of reaching out to other centres who might be willing to participate and contribute with the relevant data and deciding on a data management plan.

For a full overview on secondary and ancillary studies in SafeBoosC-III, see the link below:

<https://www.rigshospitalet.dk/english/departments/juliane-marie-centre/department-of-neonatology/research/SafeboosC-III/Sider/ancillary-studies.aspx>

Data entries have been completed

As of 1st of April, the possibility to enter new data in OpenClinica has been closed. We ended up with the following completion percentages:

- End of monitoring forms: 98.6%
- Serious adverse reaction forms: 98.3%
- 36 weeks follow-up forms: 98.6%
- Blinded 36 weeks follow up forms: 98.6%

Missing data is primarily due to parents withdrawing their infant from the trial. In one case, a centre was withdrawn from the trial by the hospital director and thus, data was not entered for two randomised participants. This is indeed a positive result. Once we have received the last GCP reports and completed the last round of central data monitoring, the statistical analyses will be initiated. For an overview of the completion process, please see the following SOP:

<https://www.rigshospitalet.dk/english/departments/juliane-marie-centre/department-of-neonatology/research/SafeboosC-III/Documents/sop-completion-of-safeboosc-iii.pdf>

Steering committee meeting

On the 28th of March, the 18th SafeBoosC-III steering committee meeting was held. Besides discussing the study proposals from the online investigator meeting on 24th of March, Markus Harboe Olsen – one of the two statisticians who will analyse the SafeBoosC-III data – presented a proposal for a secondary Bayesian analysis of the trial data. The proposal was approved by the steering group and Markus will continue developing the statistical analysis plan.

All investigators who will co-author the publication of the primary results, will also co-author the manuscript on this secondary analysis.

Minutes from the meeting can be found here:

<https://www.rigshospitalet.dk/english/departments/juliane-marie-centre/department-of-neonatology/research/SafeboosC-III/Documents/for-professionals/minutes-from-the-steering-committee-meeting-march-2022.pdf>


Data quality monitoring report

The seventh round of central data quality monitoring was conducted throughout February and March. The full report, including identified deviations in data entries and quality deficiencies, as well as the investigators response to inquiries, are available at safeboosc.eu under “Data quality reports”:

<https://www.rigshospitalet.dk/english/departments/juliane-marie-centre/department-of-neonatology/research/SafeboosC-III/Sider/good-clinical-practice.aspx>

SafeBoosC-III Follow-up

Eight centres have participants that have reached two years of corrected age, and seven centres have started completing data entries in OpenClinica. A total of 29 participants have been followed-up and 26 families have filled out the parental questionnaire. For an overview of data completion, please see below:



SafeBoosC-IIIv

We plan to apply for the Innovation foundation again to cover the trial centre costs in Copenhagen. We expect the application to be strengthened by the good process in the SafeBoosC-III trial. In addition, we have also applied for smaller grants and will receive the decisions late summer/early fall.

Thank you for your time,
Gorm, Marie, Maria and Mathias